Neurim Pharmaceuticals

About

News

Products

Business

Partners

Research




	Neurim Pharmaceuticals is a drug discovery and development company. Its first approved drug, Circadin® – prolonged release melatonin for insomnia, has been commercially available in the EU since October, 2007


	TEVA, LUNDBECK, NYCOMED
	Learn More

Insomnia

Parkinson’s disease

Asthma/COPD

To establish a leadership position in small molecule drug research and development, aimed at improving quality of life of the older patient. Read More

11 June 2009
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients.

24 September 2007

Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck

06 July 2007

Nycomed to market Circadin® for primary insomnia

29 June 2007

An Authorisation valid throughout the European Union was issued by the EMEA for Circadin®

27 April 2007

Neurim Pharmaceuticals announce that Circadin® (prolonged-release melatonin) for Primary Insomnia is recommended for approval in the EU

26 April 2007

Summary of positive opinion for Circadin® (EMEA Press Release)





	.